SymbioCellTech
Salt Lake City, US · Utah LLC
SymbioCellTech develops a cell therapy called "Neo-Islets" intended to treat Type 1 Diabetes without daily insulin injections or immunosuppressive anti-rejection drugs. The company targets the estimated 16 million people living with Type 1 Diabetes.
Founders & leadership
Board
AZ
Axel ZanderManager of LLC
GR
George ReissManager of LLC
RM
Robert Maddock, IIIManager of LLC
PH
Phil HolmesManager of LLC
AG
Allen GardnerManager of LLC
SM
Susan McKeeverManager of LLC
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 3 rounds · 2014–2017
▶$286.1KraisedAug 2017 · 3 investors · BiotechnologyRule 506(b)
▶$286.1KraisedAug 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Allen GardnerDirector
- Phil HolmesDirector
- Axel ZanderDirector, Promoter
- Susan McKeeverExecutive Officer, Director
- Robert Maddock, LLCDirector
- Christof WestenfelderExecutive Officer, Director, Promoter
- Anna GoochExecutive Officer, Director
- George ReissDirector
- Offering amount
- $2M
- Amount sold
- $286.1K
- First sale
- Aug 2017
- Incorporated
- Limited Liability Company, Utah
- Federal exemptions
- 06b
▶$1.9MraisedJun 2016 · 4 investors · BiotechnologyRule 506(b)
▶$1.9MraisedJun 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Axel ZanderDirector, Promoter
- George ReissDirector
- Robert Maddock, IIIDirector
- Anna GoochExecutive Officer, Director
- Phil HolmesDirector
- Christof WestenfelderExecutive Officer, Director, Promoter
- Allen GardnerDirector
- Susan McKeeverExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.9M
- First sale
- Jun 2016
- Incorporated
- Limited Liability Company, Utah
- Federal exemptions
- 06b
▶$2.6MraisedJun 2014 · 7 investors · BiotechnologyRule 506(b)
▶$2.6MraisedJun 2014 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christof WestenfelderExecutive Officer, Director, Promoter
- Axel ZanderDirector, Promoter
- Robert Maddock, IIIDirector
- George ReissDirector
- Anna GoochExecutive Officer, Director
- Susan McKeeverExecutive Officer
- Offering amount
- $7M
- Amount sold
- $2.6M
- First sale
- Mar 2014
- Incorporated
- Limited Liability Company, Utah
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does SymbioCellTech do?
- SymbioCellTech develops a cell therapy called "Neo-Islets" intended to treat Type 1 Diabetes without daily insulin injections or immunosuppressive anti-rejection drugs. The company targets the estimated 16 million people living with Type 1 Diabetes.
- Who founded SymbioCellTech?
- SymbioCellTech was founded by Anna Gooch, Christof Westenfelder.
- How much funding has SymbioCellTech raised?
- SymbioCellTech has disclosed $4.8M raised across 3 rounds.
- Where is SymbioCellTech headquartered?
- SymbioCellTech is headquartered in Salt Lake City, US.